Skip to main content

Table 6 Interscale correlations of EORCT QLQ-BN20

From: Translation and validation of the Urdu version of the European organization for research and treatment of cancer core quality of life questionnaire (EORTC QLQ-C30) and brain module (QLQ-BN20) in primary brain tumor patients

  FU VD M CD HA SZ DS HL IS WL BC
FU 1 0.402* 0.458* 0.346* 0.280* 0.346* 0.628* 0.245* 0.109 0.385* 0.358*
VD 0.402* 1 0.372* 0.467* 0.202* 0.167* 0.441* 0.216* 0.077 0.256* 0.288*
MD 0.458* 0.372* 1 0.568* 0.183* 0.191* 0.605* 0.203* 0.137+ 0.683* 0.400*
CD 0.346* 0.467* 0.568* 1 0.092 0.141+ 0.450* 0.046 0.235* 0.366* 0.187*
HA 0.280* 0.202* 0.183* 0.092 1 0.085 0.259* 0.134+ 0.057 0.153+ (0.258*
SZ 0.346* 0.167* 0.191* 0.141+ 0.085 1 0.254*  − 0.052  − 0.083 0.278* 0.024
DS 0.628* 0.441* 0.605* 0.450* 0.259* 0.254* 1 0.221* 0.176* 0.453* 0.348*
HL 0.245* 0.216* 0.203* 0.046 0.134  − 0.052 0.221* 1 0.325* 0.128+ 0.485*
IS 0.109* 0.077 0.137+ 0.235* 0.057  − 0.083 0.176* 0.176* 1 0.149+ 0.242*
WL 0.385* 0.256* 0.683* 0.366* 0.153+ 0.278* 0.453* 0.453* 0.149+ 1 0.350*
BC 0.358* 0.288* 0.400* 0.187* 0.258* 0.024 0.348* 0.348* 0.242* 0.350* 1
  1. FU, future uncertainty; VD, visual disorder; M, motor dysfunction; CD, communication deficit; HA, headache; SZ, seizures; DS, drowsiness; HL, hair loss; IS, itchy skin; WL, weakness in leg; BC, bladder control
  2. +Significant at p < 0.05
  3. *Significant at p < 0.01